SGPP2

Summary

SGPP2 (sphingosine-1-phosphate phosphatase 2, HGNC:19953) is a protein-coding gene on chromosome 2q36.1, encoding Sphingosine-1-phosphate phosphatase 2 (Q8IWX5). Has specific phosphohydrolase activity towards sphingoid base 1-phosphates.

The protein encoded by this gene is a transmembrane protein that degrades the bioactive signaling molecule sphingosine 1-phosphate. The encoded protein is induced during inflammatory responses and has been shown to be downregulated by the microRNA-31 tumor suppressor. Alternative splice variants encoding different isoforms have been found for this gene.

Source: NCBI Gene 130367 — RefSeq curated summary.

At a glance

• Gene–disease (curated): retinitis pigmentosa (Limited, GenCC)
• GWAS associations: 7
• Clinical variants (ClinVar): 265 total — 1 pathogenic, 1 likely-pathogenic
• Phenotypes (HPO): 1
• Dosage sensitivity (ClinGen): haploinsufficiency no evidence, triplosensitivity no evidence
• MANE Select transcript: NM_152386

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:19953
Approved symbol	SGPP2
Name	sphingosine-1-phosphate phosphatase 2
Location	2q36.1
Locus type	gene with protein product
Status	Approved
Aliases	SPP2, FLJ39004
Ensembl gene	ENSG00000163082
Ensembl biotype	protein_coding
OMIM	612827
Entrez	130367

Gene structure

Transcript identifiers

Ensembl transcripts: 4 — 4 protein_coding

ENST00000321276, ENST00000852416, ENST00000964571, ENST00000964572

RefSeq mRNA: 3 — MANE Select: NM_152386 NM_001320833, NM_001320834, NM_152386

CCDS: CCDS2453

Canonical transcript exons

ENST00000321276 — 5 exons

Exon	Start	End
ENSE00001071412	222524944	222525033
ENSE00001242313	222558347	222562621
ENSE00001242333	222424543	222424821
ENSE00001363598	222521767	222521946
ENSE00001684508	222474568	222474726

Expression profiles

Bgee: expression breadth ubiquitous, 226 present calls, max score 97.58.

FANTOM5 (CAGE): breadth broad, TPM avg 6.1114 / max 199.1813, expressed in 674 samples.

FANTOM5 promoters (13 alternative TSS)

Promoter ID	TPM avg	Samples expressed
25613	1.6961	482
25604	1.3097	257
25605	0.7067	173
25612	0.4386	240
25606	0.3902	129
25614	0.3713	181
25609	0.3454	186
25607	0.2892	145
25615	0.1482	79
25608	0.1378	73

Top tissues by expression

249 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
ileal mucosa	UBERON:0000331	97.58	gold quality
upper arm skin	UBERON:0004263	97.35	gold quality
upper leg skin	UBERON:0004262	96.92	gold quality
nasal cavity epithelium	UBERON:0005384	96.30	gold quality
mammalian vulva	UBERON:0000997	96.19	gold quality
gingival epithelium	UBERON:0001949	96.00	gold quality
gingiva	UBERON:0001828	95.46	gold quality
renal medulla	UBERON:0000362	95.01	gold quality
nipple	UBERON:0002030	94.35	gold quality
pancreatic ductal cell	CL:0002079	93.82	silver quality
kidney epithelium	UBERON:0004819	93.60	gold quality
colonic mucosa	UBERON:0000317	93.21	gold quality
epithelial cell of pancreas	CL:0000083	93.05	gold quality
mucosa of sigmoid colon	UBERON:0004993	92.95	gold quality
esophagus squamous epithelium	UBERON:0006920	92.46	gold quality
bronchial epithelial cell	CL:0002328	92.45	gold quality
islet of Langerhans	UBERON:0000006	92.27	gold quality
bronchus	UBERON:0002185	92.05	gold quality
penis	UBERON:0000989	92.03	gold quality
pons	UBERON:0000988	91.14	gold quality
lateral nuclear group of thalamus	UBERON:0002736	89.57	gold quality
middle temporal gyrus	UBERON:0002771	89.51	gold quality
epithelium of nasopharynx	UBERON:0001951	89.50	gold quality
palpebral conjunctiva	UBERON:0001812	89.42	gold quality
buccal mucosa cell	CL:0002336	89.37	gold quality
trachea	UBERON:0003126	89.07	gold quality
lower esophagus mucosa	UBERON:0035834	88.72	gold quality
skin of hip	UBERON:0001554	88.57	gold quality
duodenum	UBERON:0002114	88.52	gold quality
jejunal mucosa	UBERON:0000399	87.97	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	12.15

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

109 targeting SGPP2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-3924	100.00	72.09	2394
HSA-MIR-4283	100.00	66.42	2097
HSA-MIR-4455	100.00	65.48	1587
HSA-MIR-4692	100.00	67.32	2066
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-4514	99.99	67.10	1870
HSA-MIR-1229-3P	99.97	66.49	906
HSA-MIR-551B-5P	99.96	71.28	3493
HSA-MIR-101-3P	99.94	75.03	2230
HSA-MIR-539-5P	99.93	70.30	2855
HSA-MIR-6721-5P	99.93	68.92	2981
HSA-MIR-3119	99.92	71.34	2390
HSA-MIR-8063	99.91	69.76	3146
HSA-MIR-3671	99.90	73.04	3897
HSA-MIR-765	99.84	68.24	2442
HSA-MIR-548AZ-5P	99.83	69.94	3230
HSA-MIR-548T-5P	99.83	69.91	3220
HSA-MIR-5002-5P	99.76	70.84	1763
HSA-MIR-11181-3P	99.75	66.38	2205
HSA-MIR-6745	99.74	65.33	1321
HSA-MIR-4422	99.72	72.07	2908
HSA-MIR-4524A-3P	99.72	66.85	2406
HSA-MIR-1283	99.69	72.42	3009
HSA-MIR-4729	99.69	72.18	4233
HSA-MIR-29B-2-5P	99.67	68.98	1726
HSA-MIR-7-5P	99.67	70.53	1809
HSA-MIR-6512-3P	99.65	66.07	1468

Functional genomics

ClinGen dosage: haploinsufficiency 0 (no evidence), triplosensitivity 0 (no evidence). ClinGen Gene Dosage Map

Literature-anchored findings (GeneRIF, showing 3)

• characterization of SPP2, another member of the SPP family that may play a role in attenuating intracellular S1P signaling. (PMID:12411432)
• This study provides detailed insights into the regulation of SPP2 gene expression and suggests that SPP2 might be a novel player in pro-inflammatory signalling. (PMID:17113265)
• SGPP2, a sphingosine-1-phosphate phosphatase, is a novel vitamin D-responsive gene associated with lung function. (PMID:24274704)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio		ENSDARG00000079608
mus_musculus	Sgpp2	ENSMUSG00000032908
rattus_norvegicus	Sgpp2	ENSRNOG00000069992
drosophila_melanogaster	CG31717	FBGN0051717
caenorhabditis_elegans		WBGENE00020486

Paralogs (3): SGPP1 (ENSG00000126821), PLPP7 (ENSG00000160539), PLPP6 (ENSG00000205808)

Protein

Protein identifiers

Sphingosine-1-phosphate phosphatase 2 — Q8IWX5 (reviewed: Q8IWX5)

Alternative names: Sphingosine-1-phosphatase 2

All UniProt accessions (1): Q8IWX5

UniProt curated annotations — full annotation on UniProt →

Function. Has specific phosphohydrolase activity towards sphingoid base 1-phosphates. Has high phosphohydrolase activity against dihydrosphingosine-1-phosphate and sphingosine-1-phosphate (S1P) in vitro. Sphingosine-1-phosphate phosphatase activity is needed for efficient recycling of sphingosine into the sphingolipid synthesis pathway. May play a role in attenuating intracellular sphingosine 1-phosphate (S1P) signaling. May play a role in pro-inflammatory signaling. Plays a role in the regulation of pancreatic islet beta-cell endoplasmic reticulum stress and proliferation.

Subcellular location. Endoplasmic reticulum membrane.

Tissue specificity. Expressed strongly in kidney and heart, followed by brain, colon, small intestine and lung. Not detected in skeletal muscle, thymus, spleen, liver, placenta, and peripheral blood leukocytes.

Induction. Strongly induced by TNF, also induced by bacterial lipopolycaccharides (LPS) in neutrophils, endothelial cells, and other cell types. Not induced by growth-related factors.

Similarity. Belongs to the type 2 lipid phosphate phosphatase family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q8IWX5-1	1	yes
Q8IWX5-2	2

RefSeq proteins (3): NP_001307762, NP_001307763, NP_689599* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000326	PAP2/HPO	Domain
IPR036938	PAP2/HPO_sf	Homologous_superfamily

Pfam: PF01569

Catalyzed reactions (Rhea), 3 shown:

• sphinganine 1-phosphate + H2O = sphinganine + phosphate (RHEA:27514)
• sphing-4-enine 1-phosphate + H2O = sphing-4-enine + phosphate (RHEA:27518)
• (4R)-hydroxysphinganine 1-phosphate + H2O = (4R)-hydroxysphinganine + phosphate (RHEA:33067)

UniProt features (17 total): transmembrane region 9, region of interest 3, active site 2, chain 1, site 1, splice variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8IWX5-F1	83.19	0.54

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (3): 166 (proton donor); 213 (nucleophile); 217 (stabilizes the active site histidine for nucleophilic attack)

Function

Pathways and Gene Ontology

Reactome pathways

4 pathways

ID	Pathway
R-HSA-9845614	Sphingolipid catabolism
R-HSA-1430728	Metabolism
R-HSA-428157	Sphingolipid metabolism
R-HSA-556833	Metabolism of lipids

MSigDB gene sets: 220 (showing top): GOBP_LIPID_MODIFICATION, BENPORATH_ES_WITH_H3K27ME3, GOBP_SKELETAL_SYSTEM_DEVELOPMENT, GOCC_SECRETORY_GRANULE, REACTOME_PLATELET_ACTIVATION_SIGNALING_AND_AGGREGATION, GOBP_PHOSPHOLIPID_DEPHOSPHORYLATION, GNF2_HPN, GOBP_POLYOL_METABOLIC_PROCESS, ACEVEDO_LIVER_CANCER_WITH_H3K27ME3_UP, GOBP_MEMBRANE_LIPID_CATABOLIC_PROCESS, GOBP_SPHINGOID_METABOLIC_PROCESS, GOBP_SPHINGOLIPID_METABOLIC_PROCESS, ACEVEDO_LIVER_TUMOR_VS_NORMAL_ADJACENT_TISSUE_DN, GNF2_LCAT, HSIAO_LIVER_SPECIFIC_GENES

GO Biological Process (5): sphingosine metabolic process (GO:0006670), sphingolipid catabolic process (GO:0030149), phospholipid dephosphorylation (GO:0046839), regulation of type B pancreatic cell proliferation (GO:0061469), lipid metabolic process (GO:0006629)

GO Molecular Function (3): sphingosine-1-phosphate phosphatase activity (GO:0042392), dihydrosphingosine-1-phosphate phosphatase activity (GO:0070780), hydrolase activity (GO:0016787)

GO Cellular Component (3): endoplasmic reticulum (GO:0005783), endoplasmic reticulum membrane (GO:0005789), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
Sphingolipid metabolism	1
Metabolism of lipids	1
Metabolism	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
diol metabolic process	1
sphingoid metabolic process	1
sphingolipid metabolic process	1
lipid catabolic process	1
dephosphorylation	1
lipid modification	1
type B pancreatic cell proliferation	1
regulation of epithelial cell proliferation	1
primary metabolic process	1
lipid phosphatase activity	1
phosphatase activity	1
catalytic activity	1
cytoplasm	1
endomembrane system	1
intracellular membrane-bounded organelle	1
organelle membrane	1
nuclear outer membrane-endoplasmic reticulum membrane network	1
endoplasmic reticulum subcompartment	1
cellular anatomical structure	1

Protein interactions and networks

STRING

686 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SGPP2	SGPL1	O95470	751
SGPP2	SPHK1	Q9NYA1	701
SGPP2	SPHK2	Q9NRA0	695
SGPP2	PLPP2	O43688	657
SGPP2	UGCG	Q16739	608
SGPP2	SGMS1	Q86VZ5	595
SGPP2	S1PR3	Q99500	510
SGPP2	CERK	Q8TCT0	498
SGPP2	SPTLC1	O15269	490
SGPP2	ASAH1	Q13510	485
SGPP2	PLPP3	O14495	482
SGPP2	PLPP1	O14494	480
SGPP2	S1PR2	O95136	480
SGPP2	ACER3	Q9NUN7	478
SGPP2	ASAH2	Q9NR71	471

IntAct

8 interactions, top by confidence:

A	B	Type	Score
SGPP2	PDLIM1	psi-mi:“MI:0914”(association)	0.350
SLC15A2	LGALS8	psi-mi:“MI:0914”(association)	0.350
SLC22A5	TMEM131L	psi-mi:“MI:0914”(association)	0.350
SLC2A7	GPR89A	psi-mi:“MI:0914”(association)	0.350
SLC30A7	ESYT2	psi-mi:“MI:0914”(association)	0.350
SLC39A8	CEBPZOS	psi-mi:“MI:0914”(association)	0.350
SLC6A12	ESYT2	psi-mi:“MI:0914”(association)	0.350

BioGRID (8): PDLIM1 (Affinity Capture-MS), RNF185 (Affinity Capture-MS), SGPP2 (Affinity Capture-MS), SGPP2 (Affinity Capture-MS), SGPP2 (Affinity Capture-MS), SGPP2 (Affinity Capture-MS), SGPP2 (Affinity Capture-MS), SGPP2 (Affinity Capture-MS)

ESM2 similar proteins: A0A078H868, A0AAS4, A0JP80, A6X919, D4AD75, O70536, O77760, O77761, P23913, P35610, P53439, P56079, Q14739, Q20696, Q20735, Q28677, Q2PZI1, Q4JM44, Q4R763, Q5R7H4, Q5RK27, Q60457, Q61263, Q63632, Q63633, Q657W3, Q6AX73, Q6Z0E2, Q7T3T4, Q7TSX5, Q86VZ5, Q8IWX5, Q8NHU3, Q8VCQ6, Q91V14, Q924N4, Q965Q4, Q9D4B1, Q9FJB4, Q9H2X9

Diamond homologs: P42334, P75806, P80143, Q1MA49, Q2K2U9, Q57819, Q810K3, Q8IWX5, Q99P55, Q9BX95, Q9JI99, Q55A00, P23501, P47013

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

265 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	1
Uncertain significance	160
Likely benign	80
Benign	7

Top pathogenic / likely-pathogenic (2)

Variant ID	HGVS	Classification
562666	GRCh37/hg19 2q35-36.3(chr2:221439250-226170404)x1	Pathogenic
3027529	NM_006944.3(SPP2):c.49_52dup (p.Phe18fs)	Likely pathogenic

SpliceAI

1184 predictions. Top by Δscore:

Variant	Effect	Δscore
2:222424819:G:GT	donor_gain	1.0000
2:222474563:TTTA:T	acceptor_loss	1.0000
2:222474565:TA:T	acceptor_loss	1.0000
2:222474566:A:AG	acceptor_gain	1.0000
2:222474567:G:A	acceptor_loss	1.0000
2:222474567:G:GG	acceptor_gain	1.0000
2:222474722:GGGTT:G	donor_gain	1.0000
2:222474723:GGTTG:G	donor_gain	1.0000
2:222474724:GTT:G	donor_gain	1.0000
2:222474725:TT:T	donor_gain	1.0000
2:222474727:G:GG	donor_gain	1.0000
2:222510934:G:GT	donor_gain	1.0000
2:222521762:TGCAG:T	acceptor_loss	1.0000
2:222521763:GCAG:G	acceptor_loss	1.0000
2:222521764:CA:C	acceptor_loss	1.0000
2:222521765:A:AG	acceptor_gain	1.0000
2:222521765:AG:A	acceptor_loss	1.0000
2:222521765:AGTT:A	acceptor_gain	1.0000
2:222521765:AGTTG:A	acceptor_gain	1.0000
2:222521766:G:GG	acceptor_gain	1.0000
2:222521766:G:GT	acceptor_loss	1.0000
2:222521766:GT:G	acceptor_gain	1.0000
2:222521766:GTT:G	acceptor_gain	1.0000
2:222521766:GTTG:G	acceptor_gain	1.0000
2:222521766:GTTGG:G	acceptor_gain	1.0000
2:222521944:CAGGT:C	donor_loss	1.0000
2:222521947:G:GC	donor_loss	1.0000
2:222521947:G:GG	donor_gain	1.0000
2:222521948:T:G	donor_loss	1.0000
2:222524939:CACAG:C	acceptor_loss	1.0000

AlphaMissense

2557 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
2:222525001:A:C	S206R	0.995
2:222525003:C:A	S206R	0.995
2:222525003:C:G	S206R	0.995
2:222521796:G:C	K136N	0.993
2:222521796:G:T	K136N	0.993
2:222525016:G:T	G211W	0.992
2:222525002:G:T	S206I	0.991
2:222424656:G:C	Q18H	0.986
2:222424656:G:T	Q18H	0.986
2:222474616:T:C	F90L	0.985
2:222474618:C:A	F90L	0.985
2:222474618:C:G	F90L	0.985
2:222525005:G:C	R207T	0.985
2:222525005:G:T	R207M	0.985
2:222424667:G:A	G22E	0.982
2:222525017:G:A	G211E	0.982
2:222474679:T:A	W111R	0.980
2:222474679:T:C	W111R	0.980
2:222521879:C:A	S164Y	0.980
2:222525017:G:T	G211V	0.980
2:222525002:G:A	S206N	0.979
2:222521815:C:A	R143S	0.978
2:222521879:C:T	S164F	0.977
2:222524995:T:C	C204R	0.977
2:222525010:T:G	Y209D	0.975
2:222521795:A:T	K136M	0.974
2:222525006:G:C	R207S	0.974
2:222525006:G:T	R207S	0.974
2:222558567:G:A	G290E	0.974
2:222558555:G:A	G286E	0.973

dbSNP variants (sampled 300 via entrez): RS1000001077 (2:222529711 G>A), RS1000005376 (2:222453561 C>T), RS1000033695 (2:222530043 CAAT>C), RS1000034753 (2:222446092 A>C,G), RS1000043457 (2:222536702 T>A), RS1000075444 (2:222544261 T>C,G), RS1000085273 (2:222446385 G>A), RS1000094915 (2:222501242 A>C), RS1000097178 (2:222529498 C>A,T), RS1000119015 (2:222560939 C>A,T), RS1000156419 (2:222460345 C>T), RS1000188404 (2:222505733 A>G), RS1000246473 (2:222507110 T>C), RS1000248206 (2:222446204 A>C), RS1000256791 (2:222466733 T>C)

Disease associations

OMIM: gene MIM:612827 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
retinitis pigmentosa	Limited	Autosomal dominant

Mondo (2): inherited retinal dystrophy (MONDO:0019118), retinitis pigmentosa (MONDO:0019200)

Orphanet (1): OBSOLETE: Inherited retinal disorder (Orphanet:71862)

HPO phenotypes

1 total (1 of 1 shown, HPO-id order):

HPO	Term
HP:0000556	Retinal dystrophy

GWAS associations

7 associations (top):

Study	Trait	p-value
GCST000698_4	Osteoporosis-related phenotypes	5.000000e-07
GCST001961_15	Anorexia nervosa	7.000000e-06
GCST002812_2	Schizophrenia (inflammation and infection response interaction)	2.000000e-06
GCST003478_1	Hair greying	7.000000e-06
GCST003901_19	Cognitive decline (age-related)	6.000000e-06
GCST006436_8	Triglyceride levels	1.000000e-09
GCST007277_4	Tourette syndrome	3.000000e-06

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0007050	HSV1 seropositivity
EFO:0004530	triglyceride measurement

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D058499	Retinal Dystrophies	C11.768.585.658
D012174	Retinitis Pigmentosa	C11.270.684; C11.768.585.658.500; C16.320.290.684

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — Sphingosine 1-phosphate phosphatase

CTD chemical–gene interactions

49 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	increases expression, affects cotreatment	4
Particulate Matter	increases abundance, increases expression, affects cotreatment, decreases expression	3
Panobinostat	affects cotreatment, increases expression	2
Air Pollutants	decreases expression, increases abundance, increases expression	2
Lipopolysaccharides	increases expression, affects response to substance, affects cotreatment	2
Aflatoxin B1	decreases methylation	2
Cadmium Chloride	decreases expression, increases expression	2
p-Chloromercuribenzoic Acid	affects cotreatment, increases expression	2
aristolochic acid I	decreases expression	1
bisphenol F	affects cotreatment, increases methylation	1
propionaldehyde	increases expression	1
lead acetate	decreases expression	1
decabromobiphenyl ether	affects expression	1
trichostatin A	increases expression	1
2,4,5,2’,4’,5’-hexachlorobiphenyl	increases expression	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression, affects cotreatment	1
isobutyl alcohol	affects cotreatment, decreases expression, increases abundance	1
mercuric bromide	affects cotreatment, increases expression	1
pentanal	increases expression	1
di-n-butylphosphoric acid	affects expression	1
CGP 52608	affects binding, increases reaction	1
entinostat	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	increases expression, affects cotreatment	1
2,2’,4,4’-tetrabromodiphenyl ether	increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
jinfukang	affects cotreatment, decreases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Sunitinib	increases expression	1
Zoledronic Acid	increases expression	1
Fulvestrant	affects cotreatment, increases methylation	1

Clinical trials (associated diseases)

259 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00717080	PHASE4	COMPLETED	The Role of Capsular Tension Ring (CTR) in Anterior Capsular Contraction
NCT00000114	PHASE3	COMPLETED	Randomized Trial of Vitamin A and Vitamin E Supplementation for Retinitis Pigmentosa
NCT00000116	PHASE3	COMPLETED	Randomized Trial of DHA for Retinitis Pigmentosa Patients Receiving Vitamin A
NCT00346333	PHASE3	COMPLETED	Clinical Trial of Lutein for Patients With Retinitis Pigmentosa Receiving Vitamin A
NCT01786395	PHASE3	TERMINATED	Phase III Efficacy and Safety Clinical Study of UF-021 for Treatment of Retinitis Pigmentosa
NCT04224207	PHASE3	COMPLETED	Management of Retinitis Pigmentosa by Mesenchymal Stem Cells by Wharton’s Jelly Derived Mesenchymal Stem Cells
NCT04636853	PHASE3	COMPLETED	CB-PRP in Retinitis Pigmentosa and Dry Age-related Macular Degeneration
NCT05537220	PHASE3	ACTIVE_NOT_RECRUITING	Oral N-acetylcysteine for Retinitis Pigmentosa
NCT05800301	PHASE3	COMPLETED	Management of Retinitis Pigmentosa Via Combination of Wharton’s Jelly-derived Mesenchymal Stem Cells and Magnovision
NCT05926583	PHASE3	ACTIVE_NOT_RECRUITING	A Study of AAV5-hRKp.RPGR for the Treatment of Japanese Participants With X-linked Retinitis Pigmentosa
NCT06388200	PHASE3	ACTIVE_NOT_RECRUITING	A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa
NCT07082855	PHASE3	NOT_YET_RECRUITING	A Multicenter, Randomized, Double-Blind, Controlled Clinical Study of Minocycline for the Treatment of Retinitis Pigmentosa
NCT07290530	PHASE3	NOT_YET_RECRUITING	24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome
NCT00100230	PHASE2	COMPLETED	DHA and X-Linked Retinitis Pigmentosa
NCT00447980	PHASE2	COMPLETED	A Study of Encapsulated Cell Technology (ECT) Implant for Participants With Early Stage Retinitis Pigmentosa
NCT00447993	PHASE2	COMPLETED	A Study of Encapsulated Cell Technology (ECT) Implant for Patients With Late Stage Retinitis Pigmentosa
NCT01233609	PHASE2	COMPLETED	Trial of Oral Valproic Acid for Retinitis Pigmentosa
NCT01399515	PHASE2	COMPLETED	Efficacy and Safety of Oral Valproic Acid for Retinitis Pigmentosa
NCT01530659	PHASE2	COMPLETED	Retinal Imaging in CNTF -Releasing Encapsulated Cell Implant Treated Patients for Early-stage Retinitis Pigmentosa
NCT01560715	PHASE2	COMPLETED	Autologous Bone Marrow-Derived Stem Cells Transplantation For Retinitis Pigmentosa
NCT02609165	PHASE2	COMPLETED	Nerve Growth Factor Eye Drops Treatment in Patients With Retinitis Pigmentosa and Cystoid Macular Edema
NCT02661711	PHASE2	COMPLETED	Aflibercept for Macular Oedema With Underlying Retinitis Pigmentosa (AMOUR) Study
NCT02804360	PHASE2	UNKNOWN	Intravitreal Dexamethasone Implant in Retinitis Pigmentosa-related Macular Edema- a Retrospective Study
NCT02837640	PHASE2	UNKNOWN	Studying a Potential Protective Effect of L-Dopa on Retinitis Pigmentosa
NCT03073733	PHASE2	COMPLETED	Safety and Efficacy of Intravitreal Injection of Human Retinal Progenitor Cells in Adults With Retinitis Pigmentosa
NCT04068207	PHASE2	COMPLETED	Minocycline Treatment in Retinitis Pigmentosa
NCT04356716	PHASE2	COMPLETED	Sildenafil for Treatment of Choroidal Ischemia
NCT04604899	PHASE2	COMPLETED	Safety of Repeat Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Adult Subjects With Retinitis Pigmentosa
NCT04763369	PHASE2	UNKNOWN	Investigation of Therapeutic Efficacy and Safety of UMSCs for the Management of Retinitis Pigmentosa (RP)
NCT04864496	PHASE2	UNKNOWN	Effects of Treatment With N- Acetylcysteine on Visual Outcomes in Patients With Retinitis Pigmentosa
NCT04945772	PHASE2	COMPLETED	Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]
NCT05085964	PHASE2	TERMINATED	An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa
NCT05392179	PHASE2	COMPLETED	A Study in Subjects With Retinitis Pigmentosa
NCT06627179	PHASE2	RECRUITING	Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene
NCT06628947	PHASE2	RECRUITING	A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis Pigmentosa
NCT06912633	PHASE2	RECRUITING	Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)
NCT03763227	PHASE2	COMPLETED	Intravitreal Ranibizumab (Lucentis®) in the Treatment of Non-leaking Macular Cysts in Retinal Dystrophy
NCT00063765	PHASE1	COMPLETED	Evaluation of Safety of Ciliary Neurotrophic Factor Implants in the Eye
NCT00065455	PHASE1	COMPLETED	Investigating the Effect of Vitamin A Supplementation on Retinitis Pigmentosa
NCT00458575	PHASE1	TERMINATED	A Study to Evaluate the Safety of CNTO 2476 in Patients With Advanced Retinitis Pigmentosa